ClinicalTrials.gg
Active, not recruitingNCT07900321Updated Oct 28, 2026

Equivalence of Oral Melatonin and Oral Midazolam in Preoperative Anxiolysis for Pediatric Fast-Track Cardiac Surgery

A Phase 2/3 interventional study of Melatonin and Midazolam in Comparative Effectiveness, sponsored by Ain Shams University. Active, not recruiting at 1 site in Egypt. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Ain Shams University · Phase 2/3, Interventional, and Prevention

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2025, registered Apr 2026).
Updated Oct 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Study summary

Equivalence of Oral Melatonin and Oral Midazolam in Preoperative Anxiolysis for Pediatric Fast-Track Cardiac Surgery

Read the detailed description

Comparision between two oral drugs preoperative for pediatrics to reach a result of anxiolysis and decrease separation anexity .

02

Conditions studied

  • Comparative Effectiveness

Keywords

  • Comparision between two drugs
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,954 studies on the registry; 430 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pediatics undergoing Fast-track congenital cardiac surgery ASA 2 Informed parental consent

Exclusion criteria

Exclusion Criteria:

  • history of psychiatric illness History of used drug allergy Sever hepatic or renal disease Emergancy surgery Developmental or neurological disorder
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Melatonin group

    Drug: oral melatonin

    Drug: Melatonin

  • Active comparator
    Medazolam group

    Drug : oral midazolam

    Drug: Midazolam

Interventions

  • A group of patients will recieve oral melatonin and the other group will recieve oral midazolam

  • One group will recieve oral melatonin and the other will recieve oral midazolam

06

What researchers measure

Primary outcomes

  1. Child separation behavior

    Evaluated using Child-Parent Separation Score of 4 grades, higher score means difficult separation

    Time frame: 20 minutes after drug administration

  2. Preoperative anxiety

    Measured using Yale preoperative Anxiety scale

    Time frame: 20 minutes after drug administration and upon OR arrival

Secondary outcomes

  1. Drug acceptance between melatonin and midazolam

    regarding each drug taste, score of 3 which 3 means unpleasant taste

    Time frame: baseline, time of oral drug administration

  2. Sedation level

    Assesed by University of Michigan sedation scale, score of 4 which 4 means unarousable

    Time frame: 20 minutes after drug administration and upon OR arrival

  3. Post operative emergance agitation

    Assessed by Richmond Agitation-Sedation Scale ranging from -5 which means unarousable to +4 which means combative

    Time frame: Post extubation ranging from immediate post operative extubation to 2 hours postoperative

  4. Post operative emergance delirium

    Using Pediatric Anesthesia Emergance Delirium Scale ,ranging from 0 to 20 where 0 eans calm and agitation considered if score more than 10

    Time frame: initial assesment ( T0) at the moment of awakening ,, then every 10 minutes for 1 hour

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2026
First posted
Oct 28, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Nov 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07900321
Responsible party
Sponsor
First posted
Oct 28, 2026
Start date
Nov 1, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Melatonin · Midazolam

Start the discussion